Actionable insights straight to your inbox

Equities logo

Radient Technologies Inc. Finalizes Real Estate Transactions for Expansion and Provides Corporate Update

Radient Technologies Inc. (TSX Venture:RTI) is pleased to announce the following update on its operations and 2018 growth initiatives.

Radient Technologies Inc. (TSX Venture:RTI) is pleased to announce the following update on its operations and 2018 growth initiatives.

Finalization of Real Estate Transactions for Expansion

Further to its news release of January 9, 2018, Radient has now signed a definitive share purchase agreement with the Amnor Group Inc. (formerly 1396730 Alberta Ltd.) (the “Vendor”) to acquire a 100% interest in 1631807 Alberta Ltd., a joint venture company (the “JV”), from the Vendor (the “JV Transaction”). The JV owns the land and building that contains the 20,000 square feet manufacturing facility in Edmonton, Canada (the “Facility”) operated by Radient. Upon closing the JV Transaction, Radient will complete an expansion of the Facility. Pursuant to the JV Transaction, Radient agreed to issue 1,246,449 common shares, at a deemed price of $1.40, to the Vendor as consideration for a 100% ownership in the JV. Radient will also assume the existing mortgage on the property in the amount of $2.4 million.

The Facility is located approximately 20 kilometers from the Aurora Sky facility owned by Aurora Cannabis Inc. (“Aurora”) (TSX:ACB) (OTCQB:ACBFF) (Frankfurt:21P) (WKN:A1C4WM). The Facility has a design capacity to process 5 metric tonnes/day of biomass and has been operational since 2016. The Facility is fully GMP compliant, with a pending ACMPR license to be granted by Health Canada. Radient has already been granted the Controlled Drugs and Substances license by Health Canada that makes it a Licensed Dealer (please see Radient’s previous news release dated February 5, 2018).

In addition, Radient has entered into a real estate purchase agreement with the Amnor Group pursuant to which Radient shall purchase two parcels of land (the “Adjacent Lands”) adjacent to the Facility (the “Adjacent Lands Transaction”). Radient is purchasing the Adjacent Lands for the future expansion of Radient’s state of the art facilities housing its unique MAP™ based extraction platform to produce high quality cannabis extracts. The acquisition of the Adjacent Lands will add an additional 80,000 sq. ft. plus of real estate that will complement the existing industrial scale MAP™ Facility. As consideration for the Adjacent Lands, Radient will issue such number of common shares to the Amnor Group, at a price of $1.34, equal to $4.3 million minus the existing mortgage on the property on the closing date of the transaction. As of today’s date, the outstanding amount of the existing mortgage on the Adjacent Lands is approximately $2.2 million.

Radient has secured a $5.5 million mortgage from Moskowitz Capital (the “Mortgage”). Radient shall use a portion of the proceeds of the Mortgage to repay the existing $2.4 million mortgage from BDC Canada on the Facility as well as the mortgage on the Adjacent Lands on the closing of the transactions. The Mortgage has a term of 24 months with an interest rate of the greater of 8.50% or the Bank of Nova Scotia Prime Rate plus 5.05% per annum. The Mortgage will be secured by the Facility and the Adjacent Lands.

Harry Kaura, a director of Radient, is a control person of the Amnor Group and therefore each of the JV Transaction and the Adjacent Lands Transaction (collectively, the “Transactions”) constitutes a “related party transaction” under Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions (“MI 61- 101”). The Company is relying on exemptions from the formal valuation and minority approval requirements of MI 61-101 based on a determination that the securities of the Company are listed on the TSX Venture Exchange and that neither the fair market value of the subject matter of, nor the fair market value of the consideration for, the Transactions, insofar as it involves interested parties, exceeds 25% of the market capitalization of the Company.

Each of the Transactions remains subject to certain customary closing conditions, including the approval of the Transactions by the TSX Venture Exchange. Closing of the JV Transaction is expected to occur on or about April 30, 2018 and closing of the Mortgage and the Adjacent Lands Transaction is expected to occur on or about April 30, 2018.

Radient is not paying any finder’s fees in connection with the Transactions.

Licensing and Plant Expansion Project

The Company, having received its Dealer’s License from Health Canada’s Office of Controlled Substances for its Research & Development Laboratory located at 8223 Roper Road in February 2018, is in the review phase of its application to the Office of Medical Cannabis for the ACMPR Production License (the “ACMPR License”) for its manufacturing facility located at 4035 101 St NW in Edmonton. Approval of the ACMPR License is dependent upon, among other things, security upgrades included in the Company’s previously announced plant expansion and optimization project, scheduled for completion in the 2nd half of 2018. The Company’s application to the Office of Medical Cannabis for a Dealer’s License for its manufacturing facility is also currently under review.

Shares for Service Issuance

Radient has issued an aggregate of 44,088 common shares to third party consultants for services provided during the quarter ended March 31, 2018, pursuant to the shares for services agreements previously approved by the TSX Venture Exchange.

The common shares were issued at the TSX Venture Exchange closing share price on March 29, 2018 of $1.47.

About Radient
Radient extracts natural compounds from a range of biological materials using microwave assisted processing (“MAP™”), a patented technology platform which provides superior customer outcomes in terms of ingredient purity, yield, and cost. From its 20,000 square foot manufacturing plant in Edmonton, Alberta, Radient serves market leaders in industries that include pharmaceutical, food, beverage, natural health and personal care markets. Since 2016, Radient has expanded its offerings to enter the cannabinoids market utilizing its MAP™ platform to process and extract cannabinoids including cannabidiol and tetrahydrocannabinol from cannabis biomass. Visit more information.

In the interest of full disclosure, we call the reader’s attention to the fact that, Inc. is compensated by the companies profiled in the Spotlight Companies section. The purpose of these profiles is to provide awareness of these companies to investors in the micro, small-cap and growth equity community and should not in any way be considered as a recommendation to buy, sell or hold these securities. is not a registered broker dealer, investment advisor, financial analyst, investment banker or other investment professional. We are a publisher of original and third party news and information. All profiles are based on information that is available to the public. The information contained herein should not be considered to be complete and is not guaranteed by to be free from misstatement or errors. The views expressed are our own and not intended to be the basis for any investment decision. Readers are reminded to do their own due diligence when researching any companies mentioned on this website. Always bear in mind that investing in early-stage companies is risky and you are encouraged to only invest an amount that you can afford to lose completely without any change in your lifestyle. Equities has been compensated with cash, common shares and/or warrants for market awareness services provided.

A weekly five-point roundup of critical events in fintech, the future of finance and the next wave of banking industry transformation.